Loading...
Loading...
Puma Biotechnology, Inc.
, a development stage biopharmaceutical
company, today announced that it has reached agreement with the U.S. Food and
Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the
planned Phase III clinical trial of the Company's lead drug candidate PB272
(neratinib) in patients with HER2-positive metastatic breast cancer who have
failed two or more prior treatments (third-line disease). The SPA is a written
agreement between the Company, as the trial's sponsor, and the FDA regarding
the design, endpoints and planned statistical analysis approach of the Phase
III trial to be used in support of a New Drug Application (NDA) for PB272. The
European Medicines Agency (EMA) has also provided follow-on scientific advice
(SA) consistent with that of the FDA regarding the Company's Phase III trial
design and endpoints to be used and the ability of such design to support the
submission of a European Union (EU) Market Authorization Application (MAA).
Pursuant to the SPA and SA, the Phase III trial will be a randomized trial of
PB272 plus Xeloda versus Tykerb plus Xeloda in patients with third-line
HER2-positive metastatic breast cancer. The trial is expected to enroll
approximately 600 patients who will be randomized (1:1) to receive either
PB272 plus Xeloda or Tykerb plus Xeloda. The trial will be conducted at
approximately 150 sites in North America, Europe and Asia-Pacific. The agreed
upon co-primary endpoints of the trial are progression-free survival and
overall survival. The Company plans to use the progression-free survival data
from the trial as the basis for submission of an NDA/MAA for
Accelerated/Conditional Approval for PB272 from the regulatory agencies. Puma
anticipates that it will begin patient enrollment in this Phase III trial in
March or April of this year.
Alan H. Auerbach, Chief Executive Officer and President of Puma Biotechnology,
said, "Obtaining FDA and EMA agreement on the overall Phase III trial design,
and more specifically patient population and primary endpoints, represents an
important milestone in the global development of PB272 and for Puma as a
company. We look forward to initiating patient enrollment in the Phase III
trial shortly."
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in